13856 research outputs found
Sort by
벤즈이미다졸 화합물 및 알츠하이머 질환 또는 헌팅톤병을 치료하기 위한 그의 용도
No full text[[abstract]]하기 제시되는 화학식 (I)의 벤즈이미다졸 화합물을 개시한다. 화합물은 강력한 효능의 인간 글루타미닐 시클라제 억제제이다. 이러한 화합물 중 하나 및 제약상 허용되는 담체를 포함하는 제약 조성물 뿐만 아니라, 알츠하이머 질환 또는 헌팅톤병 치료를 필요로 하는 대상체에게 유효량의 상기 화합물을 투여함으로써 알츠하이머 질환 또는 헌팅톤병을 치료하는 방법 또한 개시한다
苯并咪唑化合物及其在制备治疗阿兹海默症或亨丁顿氏症的药物中的用途
No full text[[abstract]]本发明提供了一种如式(I)所示的苯并咪唑化合物，该化合物是有效的人类麸酸胺环化酶抑制剂。本发明还提供了一种含有该等化合物中之一化合物及医药上可接受载体的医药组合物以及一种藉由对需要治疗阿兹海默症或亨丁顿氏症的个体投予有效量的该化合物来治疗阿兹海默症或亨丁顿氏症的方法
Benzimidazole compounds and use thereof for treating alzheimer's disease or huntington's disease
No full text[[abstract]]Benzimidazole compounds of formula (I), shown below, are disclosed. The compounds are potent human glutaminyl cyclase inhibitors. Also disclosed is a pharmaceutical composition containing one of these compounds and a pharmaceutical acceptable carrier, as well as a method of treating Alzheimer's disease or Huntington's disease by administering to a subject in need thereof an effective amount of such a compound
Proline derivatives
No full text[[abstract]]Compounds useful for treating hepatitis C virus infection. The compounds are of formula (I): wherein A, B, C, D, R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, R12, m, n, p, q, r, t, u, and v are defined herein. Also disclosed is a method for treating hepatitis C virus infection with these compounds
[[alternative]]Thiazolidinone compounds and use thereof
No full text[[abstract]]A pharmaceutical composition containing a compound of Formula (I) for treating an opioid receptor-associated condition. Also disclosed is a method for treating an opioid receptor-associated condition using such a compound. Further disclosed are two sets of thiazolidinone compounds of formula (I): (i) compounds each having an enantiomeric excess greater than 90% and (ii) compounds each being substituted with deuterium
[[alternative]]Opioid receptor modulators and use thereof
No full text[[abstract]]本揭露係關於一種用以檢測一μ鴉片受體拮抗劑轉促效劑之異構調節劑的體外篩選方法，以及一種確認受試化合物為一μ鴉片受體之調節劑的體內確認方法。本揭露更提供一種使用如式(I)所示之化合物用以治療鴉片受體相關病症之方法及包含此化合物之醫藥組成物
阿片受体调节剂及其用途
No full text[[abstract]]公开了用于鉴定μ‑阿片受体的拮抗剂‑转‑激动剂的变构调节剂的体外筛选方法，以及用于确认测试化合物为这样的μ‑阿片受体的调节剂的体内方法。还公开了使用式(I)的化合物治疗阿片受体相关病症的方法以及包含此化合物的药物组合物
[[alternative]]Anticancer oral formulation
No full text[[abstract]]본 발명은 본 명세서에 기재된 유효량의 N-(3-메틸이소티아졸-5-일)-2-[1-(3-메틸이속사졸-5-일메틸)-1H-인돌-3-일]-2-옥소아세트아마이드 또는 이의 유사체, d-알파-토코페릴폴리에틸렌글리콜 1000 숙신산염(d-alpha-tocopheryl polyethylene glycol 1000 succinate, "TPGS"); 및 2-(2-에톡시에톡시)에탄올("Transcutol")을 포함하는 경구 제제에 관한 것이다. 대상에게 경구로 상기 제제를 투여하여 암을 치료하는 방법 또한 개시된다
[[alternative]]Anti-rspo3 antibodies
No full text[[abstract]]一种分离的抗体，包含：重链可变区序列的重链互补决定区CDR1、CDR2和CDR3，该重链可变区序列系选自SEQ ID NOs：2、6、10和14；以及轻链可变区序列的轻链互补决定区CDR1、CDR2和CDR3，该轻链可变区序列系选自SEQ ID NOs：4、8、12和16；其中，该抗体与RSPO3蛋白特异性地结合。An isolated antibody comprises: heavy chain complementary determining regions CDR1, CDR2, and CDR3 of a heavy chain variable region sequence selected from SEQ ID NOs: 2, 6, 10, and 14; and light chaincomplementary determining regions CDR1, CDR2, and CDR3 of a light chain variable region sequence selected from SEQ ID NOs: 4, 8, 12, and 16, wherein the antibody binds specifically to a RSPO3 protein
[[alternative]]Thiazole compounds as protein kinase inhibitors
No full text[[abstract]]本案揭露一種如下式(I)之噻唑化合物及含有這些化合物之一的醫藥組成物：其中，R1和R2如說明書之定義。本案也揭露了以噻唑化合物之一者抑制酪胺酸激酶及治療與酪胺酸激酶相關之癌症的方法